Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » Serenex Founders Hope Proteomics Leads to Serendipitous Target and Drug Discovery

Serenex Founders Hope Proteomics Leads to Serendipitous Target and Drug Discovery

May 27, 2002
Premium

TWO YEARS ago, while serving as executive vice president in charge of separations products at Dyax, Robert Dishman realized he had to find a way to get involved in the blossoming field of proteomics. With a PhD in chemistry from the University of Massachusetts, Amherst, where he made a specialty of high-performance liquid chromatography, he could see that proteomics had the potential to contribute to speeding the timeline of drug discovery.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

US to Remain in WHO

Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.

Open Spot

Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner. 

Dip Possible

A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.

Nature Papers Examine Australian Lungfish Genome, Essential E. Coli Genes

In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.

Feb
11
Featured Webinar

Virtual Molecular Tumor Board Series: HRD and DNA Damage Repair

Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Featured Webinar

Single-Cell Multiomics to Elucidate Immune Alterations in the Human Tumor Microenvironment

Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

What's Popular?

In Proteomics & Protein Research

  1. Adeptrix Using Bruker Funding, Partnership to Drive Commercialization of Immuno-MALDI Tech

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.